BIOA Fundamental Analysis - BIOAGE LABS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BIOA. BIOA was compared to 195 industry peers in the Pharmaceuticals industry. While BIOA seems to be doing ok healthwise, there are quite some concerns on its profitability. BIOA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIOA had negative earnings in the past year.

1.2 Ratios

The Return On Assets of BIOA (-24.44%) is comparable to the rest of the industry.

The Return On Equity of BIOA (-26.83%) is better than 66.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-24.44%
ROE	-26.83%
ROIC	N/A

ROA(3y)-135.29%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIOA has more shares outstanding than it did 1 year ago.

Compared to 1 year ago, BIOA has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 2.07 indicates that BIOA is not a great score, but indicates only limited risk for bankruptcy at the moment.

BIOA's Altman-Z score of 2.07 is fine compared to the rest of the industry. BIOA outperforms 66.67% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that BIOA is not too dependend on debt financing.

BIOA has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: BIOA outperforms 59.49% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.07

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

BIOA has a Current Ratio of 13.68. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 13.68, BIOA belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.

A Quick Ratio of 13.68 indicates that BIOA has no problem at all paying its short term obligations.

BIOA has a better Quick ratio (13.68) than 86.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.68
Quick Ratio	13.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BIOA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.13%.

EPS 1Y (TTM)-6.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

BIOA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.61% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y76.03%

EPS Next 2Y31.16%

EPS Next 3Y19.61%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIOA's earnings are expected to grow with 19.61% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.16%

EPS Next 3Y19.61%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BIOA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOAGE LABS INC

NASDAQ:BIOA (7/3/2025, 7:04:53 PM)

After market: 4.1409 -0.14 (-3.25%)

4.28

+0.04 (+0.94%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-06 2025-05-06/amc

Earnings (Next)N/A N/A

Inst Owners64.05%

Inst Owner Change2.82%

Ins Owners3.64%

Ins Owner Change0%

Market Cap153.44M

Analysts46.67

Price Target4.76 (11.21%)

Short Float %4.22%

Short Ratio4.54

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)20.17%

Min EPS beat(2)7.1%

Max EPS beat(2)33.23%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-17.65%

PT rev (3m)-26.31%

EPS NQ rev (1m)0.35%

EPS NQ rev (3m)7.82%

EPS NY rev (1m)1.41%

EPS NY rev (3m)9.3%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-9.49%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	105.75
P/FCF	N/A
P/OCF	N/A
P/B	0.49
P/tB	0.49
EV/EBITDA	N/A

EPS(TTM)-2.34

EYN/A

EPS(NY)-2.3

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0.04

BVpS8.74

TBVpS8.74

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.44%
ROE	-26.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-135.29%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	13.68
Quick Ratio	13.68
Altman-Z	2.07

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)133.82%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-6.13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y76.03%

EPS Next 2Y31.16%

EPS Next 3Y19.61%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-61.56%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-19.47%

EBIT Next 3Y-17.84%

EBIT Next 5YN/A

FCF growth 1Y-38.26%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-37.9%

OCF growth 3YN/A

OCF growth 5YN/A

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens